Search results
Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why - Biogen...
Benzinga· 19 hours agoNine months after the U.S. launch of Eisai Limited ESALY and Biogen Inc’s BIIB Leqembi, the first...
Q1 2024 Biogen Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 8 hours agoAnd even then you could argue we weren't fully in the mode of being able to launch because the PET scan reimbursement hadn't been cleared. But our U.S. teams for both Eisai
Analyst Report: Biogen Inc.
Morningstar Research via Yahoo Finance· 17 hours agoBiogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies ...
Japan stocks higher at close of trade; Nikkei 225 up 0.04% By Investing.com
Investing.com· 7 hours agoJapan stocks higher at close of trade; Nikkei 225 up 0.04%
For Beaten-Down Maker of Alzheimer’s Drug, Good Enough Will Do
The Wall Street Journal· 2 hours agoIn-line sales for Alzheimer’s drug Leqembi and a beat for rare-disease drug Skyclarys has Wall...
Biogen Inc (BIIB) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic ...
GuruFocus.com via Yahoo Finance· 6 hours agoA: Priya Singhal, Executive VP, Head of Development & Interim Chief Medical Officer, mentioned that they are working with Eisai to provide a subcutaneous formulation and are ...
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
Reuters· 1 day ago, opens new tab beat Wall Street estimates for first-quarter profit on Wednesday, helped by a series...
Biogen Inc (BIIB) Q1 2024 Earnings: Mixed Results Amidst Strategic Growth Efforts
GuruFocus.com via Yahoo Finance· 1 day agoFocus Founded from the merger of Biogen and Idec in 2003, Biogen Inc has grown into a prominent player in the biotechnology sector, particularly known for its multiple sclerosis ...
Biogen's stock climbs as first-quarter profit tops estimates, Alzheimer's drug uptake improves
Morningstar· 1 day agoBiogen Inc. shares (BIIB) gained 5.5% premarket on Wednesday after the company reported first-quarter profit that beat analysts' expectations amid improving traction for its ...
Biogen Beats Estimates as Alzheimer’s Drug Gains Traction
Bloomberg via Yahoo Finance· 24 hours ago(Bloomberg) -- Biogen Inc. reported first-quarter profit that beat Wall Street’s expectations as the...
